How to take Enasidenib

Enasidenib (Enasidenib), the first of its kind inhibitor targeting IDH2, was approved in the United States in 2017 for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have IDH2 mutations detected by an FDA-approved test. However, data indicate that daily oral edensidipine treatment can induce normal myeloblast differentiation even in a heavily preconditioned population, providing a therapeutic option for a patient population for which no good options have previously been available. It is also under investigation in other countries for acute myeloid leukemia.

The recommended dose of ensidipine is100 mg orally administered once daily with or without food until disease progression or unacceptable toxicity. For patients without disease progression or unacceptable toxicity, treat for at least 6 months to allow time for clinical response. Patients should swallow the tablet whole. Do not chew, split, or crush ensidipine tablets. Take by mouth at approximately the same time each day. If you vomit, miss, or do not take a dose of ensidipine at the normal time, take it as soon as possible that day and resume your normal schedule the next day.

Ensiidi plain investigational medicine is not currently on the market in the country, so it cannot be included in medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic ensidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*30 tablets produced by a Laos pharmaceutical factory may be more than 2,000 yuan per box (the price may fluctuate due to the exchange rate). Its pharmaceutical ingredients are basically the same as those of the original drugs sold abroad. For more information on overseas drug prices and specific information, please consult Yaode Medical Consultant.